About Vaxxas Vaxxas is a biotechnology company pioneering a needle-free vaccination technology designed to enhance immune response, reduce costs, and improve accessibility. The company recently ...

According to Nova One Advisor, the global genomics data analysis market size is calculated at USD 7.91 billion in 2025 and is ...

Brisbane-based ObvioHealth has signed a three-year agreement with clinical-stage biotechnology company Vaxxas to support late-stage trials.

Genomics company Illumina (NASDAQ:ILMN) in Q3 CY2025, but sales were flat year on year at $1.08 billion. Its non-GAAP profit of $1.34 per share was 14.7% above analysts’ consensus estimates. Is now ...

Australian biotech Vaxxas has signed a three-year agreement with US-based digital clinical trial specialist ObvioHealth to advance commercialisation of the Bris ...

Geographic atrophy, an advanced form of dry age-related macular degeneration, leaves almost five million people around the ...

A wireless microchip implanted beneath the retina improved vision in 81% of patients with advanced age-related macular ...

Thank you, Sabrina, and good morning, everyone. The third quarter was another exceptional quarter for GeneDx. Achieving that vision requires a fast-growing, disciplined, profitable business that ...

A new chapter in Indian healthcare has begun with the launch of Genetidoc, India’s first online genetic clinic. This groundbreaking platform makes genetic testing, DNA testing, and genetic ...

A photovoltaic retinal implant shows promise as a way to improve vision in patients with advanced age-related macular ...

A new trial shows that a wireless subretinal implant, the PRIMA system, restored central vision in patients with geographic ...